Vir Biotech begins patient dosing in phase 1 trial of EGFR─targeting PRO─XTEN dual─masked T─cell engager VIR─5525 to ...
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in the company’s phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal …